Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
ENTITY
Oryzon Genomics (ORY SM)
Watchlist
64
Analysis
Health Care
•
Spain
Oryzon Genomics, SA is a clinical stage biopharmaceutical company that develops epigenetics-based therapeutics.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Oryzon Genomics
•
24 Jun 2025 06:00
•
Issuer-paid
Oryzon Genomics — A step closer to a new treatment paradigm in BPD
Oryzon Genomics has submitted the Phase III clinical trial protocol to the FDA for its lysine-specific demethylase 1 (LSD1) inhibitor, vafidemstat,...
Edison Investment Research
Follow
196 Views
Share
bullish
•
Oryzon Genomics
•
19 May 2025 09:00
•
Issuer-paid
Oryzon Genomics — Preparations in place for an active 2025
Q125 saw Oryzon make significant headway towards Phase III for vafidemstat in BPD and clinical advancement for iadademstat across multiple...
Edison Investment Research
Follow
211 Views
Share
bullish
•
Oryzon Genomics
•
08 May 2025 14:00
•
Issuer-paid
Oryzon Genomics — €13.3m grant improves operating headroom
Oryzon Genomics has been awarded a €13.26m (US$15m) non-dilutive grant under the Med4Cure initiative, part of the Important Project of Common...
Edison Investment Research
Follow
260 Views
Share
bullish
•
Oryzon Genomics
•
24 Apr 2025 17:00
•
Issuer-paid
Oryzon Genomics — Capital raise to support long-term strategy
Oryzon has secured €30m through an equity raise (straight equity, no warrants attached) to support clinical development activities and other...
Edison Investment Research
Follow
226 Views
Share
bullish
•
Oryzon Genomics
•
15 Apr 2025 13:00
•
Issuer-paid
Oryzon Genomics — First patient dosed in iadademstat + ICI SCLC trial
Oryzon Genomics has announced that the first patient has been dosed in iadademstat’s Phase I/II trial, sponsored by the National Cancer Institute,...
Edison Investment Research
Follow
240 Views
Share
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.53.7
x